文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

接受嵌合抗原受体T细胞治疗患者的纵向患者报告结局

Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy.
PubMed 文献 · Blood Adv · 2023-01-01

本研究纵向评估接受CAR-T治疗的成人血液系统恶性肿瘤患者的生活质量、心理困扰和躯体症状,在基线、治疗后1周、1、3和6个月进行测评。共纳入103例患者,生活质量在1周时恶化(B=1.96;P<.001),抑郁在1周时加重(B=-0.32;P=0.001),至6个月时均有改善。6个月时分别有18%、22%和22%的患者报告有临床意义的抑郁、焦虑和创伤后应激障碍症状;1周时52%报告严重躯体症状,6个月时降至28%。

要点

  • CAR-T后1周生活质量和抑郁恶化,至6个月时改善
  • 6个月时18%报告临床显著抑郁,22%报告焦虑,22%报告创伤后应激障碍症状
  • 1周时52%报告严重躯体症状,6个月时降至28%

核心结论

  • CAR-T后生活质量下降、抑郁早期加重,至输注后6个月生活质量、心理困扰和躯体症状均有改善。
  • 有相当比例的患者纵向报告显著心理困扰和躯体症状。

研究设计与样本

  • 纵向研究,纳入接受CAR-T治疗的成人血液系统恶性肿瘤患者,共入组103例(符合条件142例中的103例,其中3例未接受CAR-T)。
  • 在基线、CAR-T后1周、1、3和6个月评估生活质量(癌症治疗功能评估-通用版)、心理困扰(医院焦虑抑郁量表、患者健康问卷-9、创伤后应激障碍清单)和躯体症状(埃德蒙顿症状评估量表修订版)。
  • 使用线性混合模型识别与生活质量轨迹相关的因素。

主要发现

  • 生活质量(B=1.96;P<.001)和抑郁(B=-0.32;P=0.001)在CAR-T后1周恶化,至6个月时改善。
  • 6个月时,18%报告临床显著抑郁,22%报告焦虑,22%报告创伤后应激障碍症状。
  • 1周时52%报告严重躯体症状,6个月时降至28%。
  • 在未调整线性混合模型中,较差的东部肿瘤协作组体能状态(B=1.24;P=0.042)、接受托珠单抗(B=1.54;P=0.042)以及因细胞因子释放综合征和/或神经毒性接受皮质类固醇(B=2.05;P=0.006)与较高的生活质量轨迹相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes in CAR-T are limited. We conducted a longitudinal study of adults with hematologic malignancies receiving CAR-T. We assessed quality of life (QOL; functional assessment of cancer therapy-general), psychological distress (hospital anxiety and depression scale, patient health questionnaire-9, posttraumatic stress disorder [PTSD] checklist), and physical symptoms (Edmonton symptom assessment scale-revised) at baseline, 1 week, 1, 3, and 6 months after CAR-T. We used linear mixed models to identify factors associated with QOL trajectory. We enrolled 103 of 142 eligible patients (3 did not receive CAR-T). QOL (B = 1.96; P < .001) and depression (B = -0.32; P = .001) worsened by 1 week and improved by 6 months after CAR-T. At 6 months, 18%, 22%, and 22% reported clinically significant depression, anxiety, and PTSD symptoms, respectively. At 1 week, 52% reported severe physical symptoms, declining to 28% at 6 months after CAR-T. In unadjusted linear mixed models, worse Eastern Cooperative Oncology Group performance status (B = 1.24; P = .042), receipt of tocilizumab (B = 1.54; P = .042), and receipt of corticosteroids for cytokine release syndrome and/or neurotoxicity (B = 2.05; P = .006) were associated with higher QOL trajectory. After CAR-T, QOL declined, and depression increased early, followed by improvements in QOL, psychological distress, and physical symptoms by 6 months after infusion. A significant minority of patients reported substantial psychological distress and physical symptoms longitudinally.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Johnson PC, Dhawale T, Newcomb RA, et al. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2023. PMID: 36995091. doi:10.1182/bloodadvances.2022009117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。